Carisoprodol

CAS 78-44-4 7 current records 9 historicalSmall Molecule

Who holds supplier records for Carisoprodol? 7 organisations hold a current record for Carisoprodol: an active US FDA Type II Drug Master File. A further 9 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (4), Italy (2) and Switzerland (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Carisoprodol: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/carisoprodol

Reading the evidence

  • 7 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (7)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Carisoprodol. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Carisoprodol sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (9)

Organisations whose Type II DMFs for Carisoprodol are no longer active. These show a past filing, not current supply.

Show all 9 historical records
  • India · Inactive DMF 19801, 31965 · filed Aug 2017
  • POLYDRUG LABORATORIES PVT LTD
    Inactive DMF 25687 · filed Jan 2012
  • UQUIFA MEXICO SA DE CV
    Inactive DMF 24546 · filed Jan 2011
  • ALP PHARM BEIJING CO LTD
    Inactive DMF 22118 · filed Oct 2008
  • Zhejiang Charioteer Pharmaceutical Co., Ltd.
    China · Inactive DMF 19919 · filed Nov 2006
  • France · Inactive DMF 19408 · filed May 2006
  • India · Inactive DMF 19161 · filed Feb 2006
  • CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD
    Inactive DMF 17400 · filed May 2004
  • WARD BLENKINSOP AND CO LTD
    Inactive DMF 5181 · filed Dec 1983

Overview

Carisoprodol is a centrally acting skeletal muscle relaxant used for the relief of discomfort associated with musculoskeletal conditions. It is typically used short-term and often in combination with rest, physical therapy, and other measures.

Chemical identity

IUPAC name
[2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate
Canonical SMILES
CCCC(C)(COC(=O)N)COC(=O)NC(C)C
InChIKey
OFZCIYFFPZCNJE-UHFFFAOYSA-N
Synonyms
Soma API, carisoprodol, Isomeprobamate, Carisoprodate, SOMA, Carisoprodatum, Carisoma, Isobamate, Isoprothane, Sanoma, Flexartal, Isoprotane

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Muscle Relaxant
Physiologic effect
Centrally-mediated Muscle Relaxation

Therapeutic areas

Musculoskeletal DisordersPain RelieversMuscle Relaxants

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Carisoprodol?

7 organisations hold an active US FDA Type II Drug Master File or a CEP for Carisoprodol: APITORIA PHARMA PRIVATE LTD (India), CHEMECA DRUGS PRIVATE LTD (India), HARMAN FINOCHEM LTD (India), OLON SPA (Italy), SIEGFRIED EVIONNAZ SA (Switzerland), SOLARA ACTIVE PHARMA SCIENCES LTD (India) and UQUIFA ITALIA SPA (Italy). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Carisoprodol Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 19388), CHEMECA DRUGS PRIVATE LTD (DMF 35149), HARMAN FINOCHEM LTD (DMF 21064), OLON SPA (DMF 4416), SIEGFRIED EVIONNAZ SA (DMF 5240), SOLARA ACTIVE PHARMA SCIENCES LTD (DMF 23100) and UQUIFA ITALIA SPA (DMF 17444). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Carisoprodol records mean?

9 organisations have only inactive Type II DMFs for Carisoprodol. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Carisoprodol supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Carisoprodol?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.